Impact of vaccinating boys and men against HPV in the United States

Vaccine

Volumn 28, Issue 42, 2010, Pages 6858-6867

  Elbasha, Elamin H ^a   Dasbach, Erik J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Condylomata acuminata; Cost effectiveness analysis; Disease transmission models; Herd immunity; Human papillomavirus; Intraepithelial neoplasia; Probabilitistic sensitivity analysis; Recurrent respiratory papillomatoses; Uterine cervical neoplasms; Vaccines; Vulvar, vaginal, anal, oral cavity, and oropharyngeal cancer

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANUS CANCER; ARTICLE; CANCER IMMUNIZATION; CANCER MORTALITY; CHILD; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; FEMALE; HEAD AND NECK CANCER; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 4; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL LITERATURE; PAPILLOMATOSIS; PENIS CANCER; PRECANCER AND CANCER-IN-SITU; PREVALENCE; PRIORITY JOURNAL; PROTECTION; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VAGINAL INTRAEPITHELIAL NEOPLASIA; VALVULAR INTRAEPITHELIAL NEOPLASIA; VIRUS TRANSMISSION; VULVAR INTRAEPITHELIAL NEOPLASIA; WART VIRUS;

ADOLESCENT; ADULT; CHILD; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77956874341     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.030     Document Type: Article

References (40)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. IARC Human Papillomavirus. IARC Monogr Eval Carcinog Risks Hum 2007, 90.
3. Institute of Medicine Vaccines for the 21st century: a tool for decisionmaking 2000, National Academy of Sciences, Washington.
4. Sanders G.D., Taira A.V. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003, 9(1):37-48.
5. Kulasingam S.L., Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290(6):781-789.
6. Chesson H.W., Ekwueme D.U., Saraiya M., Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008, 14(2):244-251.
7. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Eng J Med 2009, 359(8):821-832.
8. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus (HPV) vaccination strategies. Emerg Infect Dis 2007, 13(1):28-41.
9. Elbasha E.H., Dasbach E.J., Insinga R.P., Haupt R.M., Barr E. Age-based programs for vaccination against HPV. Value Health 2009, 12(5):697-707.
10. Pisani P., Parkin D.M., Munoz N., Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997, 6(6):387-400.
11. Koutsky L.A. Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102(5A):3-8.
12. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-475.
13. Elbasha E.H., Dasbach E.J., Insinga R.P. A multi-type HPV transmission model: assessing the epidemiologic and economic impact of a quadrivalent HPV vaccine. Bull Math Biol 2008, 70(8):2126-2176.
14. Hethcote H.W. An age-structured model of pertussis transmission. Math Biosci 1997, 145(2):89-136.
15. U.S. Bureau of Labor Statistics. Consumer price index detailed report tables (Tables 1A-23A). ; 2009 [accessed 15.10.09]. http://www.bls.gov/cpi/cpi_dr.htm.
16. Cost-Effectiveness in health and medicine. Report of the panel on cost-effectiveness in health and medicine 1996, Oxford University Press, New York. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein (Eds.).
17. Blower S.M., Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994, 62(2):229-243.
18. Weinstein M.C., Toy E.L., Sandberg E.A., Neumann P.J., Evans J.S., Kuntz K.M., et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001, 4(5):348-361.
19. Fenwick E., O'Brien B., Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004, 13(5):405-415.
20. Eichler H.G., Kong S.X., Gerth W.C., Mavros P., Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds are expected to emerge?. Value Health 2004, 7(5):518-528.
21. Kim J.J., Goldie S.J. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:b3884.
22. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10(11):1915-1923.
23. Dasbach E.J., Elbasha E.H., Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006, 28:88-100.
24. Rosen A.B., Spaulding A.B., Greenberg D., Palmer J.A., Neumann P.J. Patient adherence: a blind spot in cost-effectiveness analyses?. Am J Manag Care 2009, 15(9):626-632.
25. Nelson J., Bittner R., Bounds L., Zhao S., Baggs J., et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health 2009, 99:S389-S397.
26. CDC's Advisory Committee on Immunization Practices (ACIP). Summary report, Atlanta, Georgia. ; June 24-26, 2009 [accessed 18.06.10]. http://www.cdc.gov/vaccines/recs/acip/downloads/min-jun09.pdf.
27. Kim J.J., Wright T.C., Goldie S.J. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002, 287(18):2382-2390.
28. Merck & Co., Inc. Unpublished data; 2009.
29. Insinga R.P., Dasbach E.J., Myers E.R. The health and economic burden of genital warts in a set of private U.S. Health Plans Clin Infect Dis 2003, 36(11):1397-1403.
30. Chesson H.W., Forhan S.E., Gottlieb S.L., et al. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 2008, 26(35):4513-4518.
31. Hu D., Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198(5):500.e1-500.e7.
32. Insinga R.P, Glass A.G., Myers E.R., Rush B.B. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007, 27(4):414-422.
33. Myers E.R., Green S., Lipkus I. Patient preferences for health states related to HPV infection: visual analog scales vs time trade-off elicitation. Proceedings of the 21st international papillomavirus conference, Mexico 2004.
34. Wenzel L., DeAlba I., Habbal R., Kluhsman B.C., Fairclough D., Krebs L., et al. Quality of life in long-term cervical cancer survivors. Gynecol Oncol 2005, 97(2):310-317.
35. Lindman J.P., Lewis L.S., Accortt N., et al. Use of the Pediatric Quality of Life Inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005, 114(7):499-503.
36. Weiss TW, Rosenthal SL, Zimet GD, Ma L, Good MB, Vichnin MD. Adherence with the quadrivalent HPV vaccine among insured US females. Poster presentation international papillomavirus conference, Malmo, Sweden; May 8-14, 2009.
37. CDC National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2008. MMWR 2009, 58(36):997-1001.
38. Pisu M., Meltzer M., Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison immates. Vaccine 2002, 21(3-4):312-321.
39. Fraser C., Tomassini J.E., Xi L.X., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007, 25(21):4324-4333.
40. Gold M.R., Franks P., McCoy K.I., Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36(6):778-792.